Awaiting development: Guidance and quality standards

Showing 171 to 180 of 275

Guidance and quality standards awaiting development
Title	Type
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587]	Technology appraisal guidance
Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]	Technology appraisal guidance
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]	Technology appraisal guidance
Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6566]	Technology appraisal guidance
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]	Technology appraisal guidance
PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]	Technology appraisal guidance
Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]	Technology appraisal guidance
Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]	Technology appraisal guidance
Pridopidine for treating Huntington's disease [ID6525]	Technology appraisal guidance
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]	Technology appraisal guidance